Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 8/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.39 |
| ▸ | GBA1 | P04062 | 1/20 | 0.38 |
| ▸ | CTSD | P07339 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8246025 | 1.00 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3GBA1CTSD | |
| SCHEMBL714998 | 1.00 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3GBA1CTSD | |
| SCHEMBL728811 | 1.00 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3GBA1CTSD | |
| SCHEMBL9759607 | 1.00 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3GBA1CTSD | |
| SCHEMBL29258683 | 0.82 | SLC6A2 (0.41) | SLC6A2SLC6A4 | |
| SCHEMBL26121856 | 0.82 | SLC6A2 (0.41) | SLC6A2SLC6A4 | |
| SCHEMBL8245028 | 0.81 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3GBA1CTSD | |
| SCHEMBL748784 | 0.79 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3GBA1CTSD | |
| SCHEMBL13566529 | 0.79 | OPRM1 (0.50) | SLC6A2SLC6A4 | |
| SCHEMBL29218400 | 0.79 | OPRM1 (0.47) | SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080085915-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF GASTROINTESTINAL AND CENTRAL NERVOUS SYSTEM DISORDERS | ARYX THERAPEUTICS, INC. | 2008-04-10 | — | — | US | disclosed |
| US-20080085915-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF GASTROINTESTINAL AND CENTRAL NERVOUS SYSTEM DISORDERS | ARYX THERAPEUTICS, INC. | 2008-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085915-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF GASTROINTESTINAL AND CENTRAL NERVOUS SYSTEM DISORDERS | CCKBR, HRH2, GRPR | SLC6A2 95/4885SLC6A4 143/4885SLC6A3 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.